Hyeyeol Bae1, Junichi Tsuchiya1, Takehito Okamoto2, Ikuko Ito2, Yusuke Sonehara3, Fumiko Nagahama4, Kazunori Kubota1, Ukihide Tateishi5,6. 1. Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 2. Imaging Service Department, MICRON Inc, Tokyo, Japan. 3. Clinical Development, Solasia Pharma K.K, Tokyo, Japan. 4. Asia Clinical Development, Solasia Pharma K.K, Tokyo, Japan. 5. Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, Japan. ttisdrnm@tmd.ac.jp. 6. Japan-Quantitative Imaging Biomarker Alliance (J-QIBA), Japan Radiologic Society, Tokyo, Japan. ttisdrnm@tmd.ac.jp.
Abstract
PURPOSE: In an Asian international multicenter phase II trial conducted in patients with peripheral T-cell lymphoma (PTCL), [F-18]FDG-PET/CT was used for evaluation of the therapeutic response. Standardization of the PET/CT scanners was necessary before patient enrollment. We therefore standardized the scanners by phantom tests based on the profile approved by the Quantitative Imaging Biomarkers Alliance (QIBA) of Radiological Society of North America (RSNA). MATERIALS AND METHODS: The tests were conducted on 12 scanners in 12 facilities in compliance with the QIBA Profile and used National Electrical Manufacturers Association (NEMA) International Electrotechnical Commission (IEC) body phantoms. We measured three parameters (standardized uptake value [SUV], resolution and noise) and adjusted the imaging parameter values. The indexes recommended in the Japanese Society of Nuclear Medicine (JSNM) guideline were also evaluated. RESULTS: In a total of 12 facilities, 6 facilities required no change in imaging conditions and 6 facilities required changes in imaging parameters. After revision, the three measurements (SUV, resolution and noise) met QIBA criteria at all sites, but 10 of the 12 scanners did not meet JSNM criteria. CONCLUSION: We standardized imaging conditions using phantoms as required in the RSNA-QIBA profile for response evaluation by [F-18]FDG PET/CT images in a multicenter study.
PURPOSE: In an Asian international multicenter phase II trial conducted in patients with peripheral T-cell lymphoma (PTCL), [F-18]FDG-PET/CT was used for evaluation of the therapeutic response. Standardization of the PET/CT scanners was necessary before patient enrollment. We therefore standardized the scanners by phantom tests based on the profile approved by the Quantitative Imaging Biomarkers Alliance (QIBA) of Radiological Society of North America (RSNA). MATERIALS AND METHODS: The tests were conducted on 12 scanners in 12 facilities in compliance with the QIBA Profile and used National Electrical Manufacturers Association (NEMA) International Electrotechnical Commission (IEC) body phantoms. We measured three parameters (standardized uptake value [SUV], resolution and noise) and adjusted the imaging parameter values. The indexes recommended in the Japanese Society of Nuclear Medicine (JSNM) guideline were also evaluated. RESULTS: In a total of 12 facilities, 6 facilities required no change in imaging conditions and 6 facilities required changes in imaging parameters. After revision, the three measurements (SUV, resolution and noise) met QIBA criteria at all sites, but 10 of the 12 scanners did not meet JSNM criteria. CONCLUSION: We standardized imaging conditions using phantoms as required in the RSNA-QIBA profile for response evaluation by [F-18]FDG PET/CT images in a multicenter study.
Authors: Daniel C Sullivan; Nancy A Obuchowski; Larry G Kessler; David L Raunig; Constantine Gatsonis; Erich P Huang; Marina Kondratovich; Lisa M McShane; Anthony P Reeves; Daniel P Barboriak; Alexander R Guimaraes; Richard L Wahl Journal: Radiology Date: 2015-08-12 Impact factor: 11.105
Authors: Andrew J Buckler; Linda Bresolin; N Reed Dunnick; Daniel C Sullivan; Hugo J W L Aerts; Bernard Bendriem; Claus Bendtsen; Ronald Boellaard; John M Boone; Patricia E Cole; James J Conklin; Gary S Dorfman; Pamela S Douglas; Willy Eidsaunet; Cathy Elsinger; Richard A Frank; Constantine Gatsonis; Maryellen L Giger; Sandeep N Gupta; David Gustafson; Otto S Hoekstra; Edward F Jackson; Lisa Karam; Gary J Kelloff; Paul E Kinahan; Geoffrey McLennan; Colin G Miller; P David Mozley; Keith E Muller; Rick Patt; David Raunig; Mark Rosen; Haren Rupani; Lawrence H Schwartz; Barry A Siegel; A Gregory Sorensen; Richard L Wahl; John C Waterton; Walter Wolf; Gudrun Zahlmann; Brian Zimmerman Journal: Radiology Date: 2011-02-15 Impact factor: 11.105
Authors: Dai Chihara; Michelle A Fanale; Roberto N Miranda; Mansoor Noorani; Jason R Westin; Loretta J Nastoupil; Fredrick B Hagemeister; Luis E Fayad; Jorge E Romaguera; Felipe Samaniego; Francesco Turturro; Hun J Lee; Sattva S Neelapu; M Alma Rodriguez; Michael Wang; Nathan H Fowler; Richard E Davis; L Jeffrey Medeiros; Chitra Hosing; Yago L Nieto; Yasuhiro Oki Journal: Br J Haematol Date: 2016-12-16 Impact factor: 6.998
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Dashnamoorthy Ravi; Savita Bhalla; Ronald B Gartenhaus; Jennifer Crombie; Irawati Kandela; Jaya Sharma; Andrew Mazar; Andrew M Evens Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: D J Sargent; L Rubinstein; L Schwartz; J E Dancey; C Gatsonis; L E Dodd; L K Shankar Journal: Eur J Cancer Date: 2008-12-16 Impact factor: 9.162
Authors: Shannon M Matulis; Alejo A Morales; Lucy Yehiayan; Claire Croutch; Delia Gutman; Yong Cai; Kelvin P Lee; Lawrence H Boise Journal: Mol Cancer Ther Date: 2009-05-05 Impact factor: 6.261